Export file:

Format

  • RIS(for EndNote,Reference Manager,ProCite)
  • BibTex
  • Text

Content

  • Citation Only
  • Citation and Abstract

The impact of exclusive enteral nutrition on the intestinal microbiota in inflammatory bowel disease

Department of Paediatrics, University of Otago Christchurch, Christchurch, New Zealand

It is increasingly clear that the intestinal microbiota plays key roles in the pathogenesis of the conditions known as Crohn disease and ulcerative colitis (jointly known as the inflammatory bowel diseases). Perturbations of the microbiota, termed dysbiosis, are present at diagnosis and likely reflect earlier environmental influences along with interactions with intestinal immune responses. Over the last two decades, there has been increasing interest in the use of a nutritional therapy to induce remission of active Crohn disease. Amongst a number of recent studies focusing on the putative mechanisms of action of enteral nutrition in Crohn disease, there have been several reports illustrating profound interactions between this nutritional therapy and the intestinal microbiota. Although at present it is still not clear how these changes relate to concurrent improvements in inflammation, it has become an area of increasing interest. This review article focuses on the impacts of nutritional therapy in individuals with active Crohn disease and overviews the most recent data arising from international studies.
  Figure/Table
  Supplementary
  Article Metrics

Keywords Crohn disease; inflammatory bowel disease; therapy; nutrition; intestinal microbiota; inflammation; dysbiosis

Citation: Andrew S Day. The impact of exclusive enteral nutrition on the intestinal microbiota in inflammatory bowel disease. AIMS Microbiology, 2018, 4(4): 584-593. doi: 10.3934/microbiol.2018.4.584

References

  • 1. Lemberg DA, Day AS (2015) Crohn disease and colitis in children: An update for 2014. J Paediatr Child H 51: 266–270.    
  • 2. McGovern DP, Kugathasan S, Cho JH (2015) Genetics of inflammatory bowel diseases. Gastroenterology 149: 1163–1176.    
  • 3. Bernstein CN (2017) Review article: changes in the epidemiology of inflammatory bowel disease-clues for aetiology. Aliment Pharm Therap 46: 911–919.    
  • 4. Sairenji T, Collins KL, Evans DV (2017) An update on inflammatory bowel disease. Prim Care 44: 673–692.    
  • 5. Critch J, Day AS, Otley AR, et al. (2012) Clinical report: The utilization of enteral nutrition for the control of intestinal inflammation in pediatric Crohn disease. J Pediatr Gastr Nutr 54: 298–305.    
  • 6. Day AS, Lopez RN (2015) Exclusive enteral nutrition in children with Crohn disease. World J Gastroenterol 21: 6809–6816.    
  • 7. Voitk AJ, Echave V, Feller JH, et al. (1973) Experience with elemental diet in the treatment of inflammatory bowel disease. Is this primary therapy? Arch Surg 107: 329–333.
  • 8. O'Morain C, Segal AW, Levi AJ (1984) Elemental diet as primary-treatment of acute Crohn's disease-A controlled trial. Brit Med J 288: 1859–1862.    
  • 9. Whitten KE, Leach ST, Bohane TD, et al. (2010) Effect of exclusive enteral nutrition on bone turnover in children with Crohn's disease. J Gastroenterol 45: 399–405.    
  • 10. Werkstetter KJ, Schatz SB, Alberer M, et al. (2013) Influence of exclusive enteral nutrition therapy on bone density and geometry in newly diagnosed pediatric Crohn's disease patients. Ann Nutr Metab 63: 10–16.    
  • 11. Afzal NA, Addai S, Fagbemi A, et al. (2002) Refeeding syndrome with enteral nutrition in children: a case report, literature review and clinical guidelines. Clin Nutr 21: 515–520.    
  • 12. Akobeng AK, Thomas AG (2010) Refeeding syndrome following exclusive enteral nutritional treatment in Crohn disease. J Pediatr Gastr Nutr 51: 364–366.
  • 13. Schulman JM, Pritzker L, Shaoul R (2017) Maintenance of remission with partial enteral nutrition therapy in pediatric Crohn's disease: A retrospective study. Can J Gastroenterol 2017: 5873158.
  • 14. Nakahigashi M, Yamamoto T, Sacco R, et al. (2016) Enteral nutrition for maintaining remission in patients with quiescent Crohn's disease: current status and future perspectives. Int J Colorectal Dis 31: 1–7.    
  • 15. Hirai F, Ishihara H, Yada S, et al. (2013) Effectiveness of concomitant enteral nutrition therapy and infliximab for maintenance treatment of Crohn's disease in adults. Digest Dis Sci 58: 1329–1334.    
  • 16. Yamamoto T, Shiraki M, Nakahigashi M, et al. (2013) Enteral nutrition to suppress postoperative Crohn's disease recurrence: a five-year prospective cohort study. Int J Colorectal Dis 28: 335–340.    
  • 17. Day AS (2015) Inflammatory bowel disease and the intestinal microbiota. J Pediatr Biochem 5: 60–64.    
  • 18. McIlroy J, Ianiro G, Mukhopadhya I, et al. (2018) Review article: the gut microbiome in inflammatory bowel disease-avenues for microbial management. Aliment Pharm Therap 47: 26–42.    
  • 19. Sokol H, Pigneur B, Watterlot L, et al. (2008) Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. P Natl Acad Sci USA 105: 16731–16736.    
  • 20. Quévrain E, Maubert MA, Michon C, et al. (2016) Identification of an anti-inflammatory protein from Faecalibacterium prausnitzii, a commensal bacterium deficient in Crohn's disease. Gut 65: 415–425.    
  • 21. Madsen KL (2001) Inflammatory bowel disease: lessons from the IL-10 gene-deficient mouse. Clin Invest Med 24: 250–257.
  • 22. Rutgeerts P, Goboes K, Peeters M, et al. (1991) Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum. Lancet 338: 771–774.    
  • 23. D'Haens GR, Geboes K, Peeters M, et al. (1998) Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 114: 262–267.    
  • 24. Rutgeerts P, Hiele M, Goboes K, et al. (1995) Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 108: 1617–1621.    
  • 25. de Jong NSH, Leach ST, Day AS (2007) Polymeric formula has direct anti-inflammatory effects on enterocytes in an in vitro model of intestinal inflammation. Digest Dis Sci 52: 2029–2036.    
  • 26. Nahidi L, Leach ST, Mitchell HM, et al. (2013) Nutritional therapy modulates inflammation and improves altered barrier function in a mouse model of colitis. Gastroenterology 144: S532.
  • 27. Nahidi L, Day AS, Lemberg DA, et al. (2012) Differential effects of nutritional and non-nutritional therapies on intestinal barrier function in an in vitro model. J Gastroenterol 47: 107–117.    
  • 28. Pryce-Millar E, Murch SH, Heuschkel RB (2004) Enteral nutrition therapy in Crohn's disease changes the mucosal flora. J Pediatr Gastr Nutr 39: 289.
  • 29. Lionetti P, Callegari ML, Ferrai S, et al. (2005) Enteral nutrition and microflora in pediatric Crohn's disease. JPEN-Parenter Enter 29: S173–S175.    
  • 30. Leach ST, Mitchell HM, Eng WR, et al. (2008) Sustained modulation of intestinal microflora by exclusive enteral nutrition used to treat children with Crohn's disease. Aliment Pharm Therap 28: 724–733.    
  • 31. Gerasimidis K, Bertz M, Hanske L, et al. (2014) Decline in presumptively protective gut bacterial species and metabolites are paradoxically associated with disease improvement in pediatric Crohn's disease during enteral nutrition. Inflamm Bowel Dis 20: 861–871.    
  • 32. Kaakoush NO, Day AS, Leach ST, et al. (2015) Effect of exclusive enteral nutrition on the microbiota of children with newly diagnosed Crohn's disease. Clin Transl Gastroen 6: e71.    
  • 33. Quince C, Ijaz UZ, Loman N, et al. (2015) Extensive modulation of the fecal metagenome in children with Crohn's disease during exclusive enteral nutrition. Am J Gastroenterol 110: 1718–1729.    
  • 34. Lewis JD, Chen EZ, Baldassano RN, et al. (2015) Inflammation, antibiotics, and diet as environmental stressors of the gut microbiome in pediatric Crohn's disease. Cell Host Microbe 18: 489–500.    
  • 35. Schwerd T, Frivolt K, Clavel T, et al. (2016) Exclusive enteral nutrition in active pediatric Crohn disease: Effects on intestinal microbiota and immune regulation. J Allergy Clin Immun 138: 592–596.    
  • 36. Dunn KA, Moore-Connors J, MacIntyre B, et al. (2016) Early changes in microbial community structure are associated with sustained remission after nutritional treatment of pediatric Crohn's disease. Inflamm Bowel Dis 22: 2853–2862.    
  • 37. Jia W, Whitehead RN, Griffiths L, et al. (2010) Is the abundance of Faecalibacterium prausnitzii relevant to Crohn's disease? FEMS Microbiol Lett 310: 138–144.    
  • 38. Shiga H, Kajiura T, Shinozaki J, et al. (2012) Changes of faecal microbiota in patients with Crohn's disease treated with an elemental diet and total parenteral nutrition. Digest Liver Dis 44: 736–742.    
  • 39. Berntson L, Hedlund-Treutiger I, Alving K (2016) Anti-inflammatory effect of exclusive enteral nutrition in patients with juvenile idiopathic arthritis. Clin Exp Rheumatol 34: 941–945.
  • 40. Berntson L, Agback P, Dicksved J (2016) Changes in fecal microbiota and metabolomics in a child with juvenile idiopathic arthritis (JIA) responding to two treatment periods with exclusive enteral nutrition (EEN). Clin Rheumatol 35: 1501–1506.    

 

This article has been cited by

  • 1. Tai L. Guo, Yingjia Chen, Hannah Shibo Xu, Callie M. McDonough, Guannan Huang, Gut microbiome in neuroendocrine and neuroimmune interactions: The case of genistein, Toxicology and Applied Pharmacology, 2020, 115130, 10.1016/j.taap.2020.115130

Reader Comments

your name: *   your email: *  

© 2018 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution Licese (http://creativecommons.org/licenses/by/4.0)

Download full text in PDF

Export Citation

Copyright © AIMS Press All Rights Reserved